Sanofi has joined Eli Lilly and Novo Nordisk as the last of the 3 biggest suppliers of insulin in the US to announce price cuts and caps for out-of-pocket costs in insulin. The French drugmaker announced Thursday that it will be capping the out-of-pocket costs of its most popular insulin, Lantus to $35 per month for individuals with private insurance as the cap already exists for those without insurance. According to the American Diabetes Association, about 8.4 million in the US with diabetes rely on insulin and Eli Lilly, Novo Nordisk, and Sanofi supply nearly 90% of the insulin in the US. To read more about Sanofi’s price cuts, click here.
Comments are closed.